Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Investor Presentation (November 2019)
25 slides from Genocea Biosciences's investor presentation, Nov 19, 2019
Slide 1: Next generation neoantigen immunotherapies
Next generation neoantigen immunotherapies | CONFIDENTIAL 1
Slide 2: Forward-looking statements disclaimer
This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning our possible or ass
Slide 3: About: Differentiated Immunotherapies Through Precision Antigen Selection
A b o u t Differentiated Immunotherapies Through Precision Antigen Selection GEN - 009 GEN-011 Neoantigen Personalized immune Neoantigen vaccine response profiling cell therapy | CONFIDENTIAL 3
Slide 4: Antigen Selection: The Critical Differentiator
Antigen Selection: The Critical Differentiator 1 st Generation Therapies • Prediction-based neoantigen vaccines • TIL therapy (non -specific) Unmet Needs • Relevant antigen identification • Inhibitory antigen exclusion N e x t W a v e Immunotherapies based on antigens customized both to tumor and im
Slide 5: Personalized immune response profiling
A b o u t Personalized immune response profiling Identifies antigens of proven T cell responses Unique and relevant biological readout Optimal approach for identifying both anti-tumor and pro- tumor (inhibitory) responses TARGETS MATTER Comprehensive and flexible For any patient, any antigen type, a
Slide 6: Profiles the T cell Immune Repertoire for Each Patient
Profiles the T cell Immune Repertoire for Each Patient Inhibitory antigen: suppresses anti-tumor T cell response | CONFIDENTIAL 6
Slide 7: Profiling Both T cell and Tumor Critical to Antigen Selection
Profiling Both T cell and Tumor Critical to Antigen Selection ATLAS: Antigens eliciting anti-tumor T cell response T cell Identifies a nt i ge n s Surface peptides relevant to T cell receptor recognized by T cells Relevance t u m o r a n d Candidate antigen i m m u n e syste m – MHC molecule Peptide
Slide 8: Important Potential Implications of Inhibitory Responses: Reversing Efficacy
Important Potential Implications of Inhibitory Responses Inclusion of Inhibitory Neoantigens Can Reverse Efficacy of a Protective Therapy Vaccine Typical s.c. endpoint >3000mm3 D0 D3 D10 D17 B16F10 s.c. 3000 Vehicle (PBS) 1,600 Adjuvant only 1,000 (S10 + M30 + Trp2) 2500 M30 + Trp2 + adjuvant 1,400
Slide 9: Clinical Data Suggest ICI Failure May Be Influenced by Inhibitory Responses
Important Potential Implications of Inhibitory Responses Clinical Data Suggest ICI Failure May Be Influenced by Inhibitory Responses 70% 60% 50% Non-responder Responder 40% Circle size represents tumor mutational burden (TMB) 30% % Stimulatory % 20% 10% 0% 0% 5% 10% 15% 20% 25% % Inhibitory Pre-trea
Slide 10: ATLAS Has a Compelling Suite of Novel Shared Antigens
ATLAS Has a Compelling Suite of Novel Shared Antigens Shared neoantigens Novel TAAs Novel viral antigens • 10 shared neoantigens identified • CRC and NSCLC • EBV from 20 shared mutations (n = 63 • Several known TAAs shown to patients) have predominantly inhibitory • 7 have not been found to be respo
Slide 11: ATLAS Antigens Drive Next-Generation Immunotherapies
ATLAS Antigens Drive Next-Generation Immunotherapies Tailored to tumor and immune system • Expressed by tumor • Immunogenic Next Wave I/O D r i v e a n t i - tumor responses • Rule out inhibitory responses Genocea-owned • Include CD8 + and CD4 + Antigen selectivity & Excluding inhibitory for partner
Slide 12: Drives Emerging Immunotherapy Pipeline
Drives Emerging Immunotherapy Pipeline D i s c o v e r y P r e - IND P h a s e 1 / 2 a P i v o t a l Status & Anticipated Milestones GEN-009 - Neoantigen cancer vaccine • Pioneering immunogenicity: ASCO 2019 Top 10 study • Preliminary clinical results in mid-2020 GEN-011 - Neoantigen T cell therapy
Slide 13: GEN-009: Generating unprecedented Neoantigen immune responses
GEN - 009 Generating unprecedented Neoantigen immune responses V a c c i n e | CONFIDENTIAL 13
Slide 14: GEN-009: Optimized Neoantigen Vaccine
GEN - 009 Optimized Neoantigen Vaccine Collect tumor ATLAS to select Synthesize vaccine Deliver GEN-009 to and blood neoantigens of pre- (synthetic long clinical site samples, existing CD4 + and peptides + Poly ICLC) sequence exome CD8 + T cell responses Excludes inhibitory neoantigens | CONFIDENTIA
Slide 15: GEN-009 Phase 1/2a Trial Part A
T r i a l GEN - 009 Phase 1/2a Trial Designed to Showcase Vaccine Benefits In ICI Patients P a r t A • Patient cohort: No evidence of disease • Multiple tumor types with ICI approval • Objectives: safety, immunogenicity • Enrollment complete 15 | CONFIDENTIAL 15
Slide 16: Enables Unparalleled Vaccine Immune Responses
Enables Unparalleled Vaccine Immune Responses Frequency % neoantigens with immune responses 60% 99% Best Peer Results 1 GEN - 0092 Potential Patient Benefits Response breadth to prevent 1 Sahin, et al, Nature 2017 (N=8); Ott, et al, Nature 2017 (N=8) 2 N=8 tumor escape • Results shown represent high
Slide 17: Enables Unparalleled Vaccine Immune Responses: Ex Vivo and IVS Assays
Enables Unparalleled Vaccine Immune Responses E x V i v o Assay (effector function) IVS Assay (central memory) Best peer results 1 GEN - 0092 Best peer results 1 GEN - 0092 51% 87% 41% 57% 57% 23% 17% 0% Potential Patient Benefits Potential Patient Benefits Rapid tumor killing Durable efficacy 1 Sah
Slide 18: GEN-009 Phase 1/2a Trial Part B
T r i a l GEN - 009 Phase 1/2a Trial Designed to Showcase Vaccine Benefits in ICI Pat i e nt s P a r t B • Combination of GEN-009 and standard-of-care PD-1 based regimen intended in cohorts of patients with advanced disease • Vaccination after response to PD -1 regimen determined • Objectives: Safet
Slide 19: GEN-011: Potential first-in-class solid tumor T cell therapy
GEN - 011 Potential first-in-class solid Neoantigen tumor T cell therapy T cell Therapy | CONFIDENTIAL 19
Slide 20: TIL Therapy Has Changed the Narrative For Neoantigen-specific T cell Therapy
TIL Therapy Has Changed the Narrative For Neoantigen - s p e c i f i c T cell Therapy to Treat Solid Tumors Tumor infiltrating lymphocyte (TIL) therapy has delivered durable efficacy in hard -to- treat solid tumor patients • 44% ORR in late-stage cervical cancer patients • Similar benefits in heavil
Slide 21: Lessons Learned From TIL Therapy
Lessons Learned From TIL Therapy M u l t i p l e C D 4 + a n d C D 8 + T c e l l s neoantigen targets CD4 + T cells support activity • Attacks tumor heterogeneity, and persistence of CD8 + T limits tumor escape CD4+ CD8+ cells and can directly kill • Intracellular as well as tumor cells extracellula
Slide 22: Still Significant Opportunities to Enhance T cell Therapy for Solid Tumors
Still Significant Opportunities to Enhance T cell Therapy for Solid Tumors Approaches to Address Increase target breadth & specificity TILs only target a limited proportion of neoantigens Neoantigen selection via Avoid deleterious T cell responses Inhibitory, pro -tumor responses to neoantigens shou
Slide 23: GEN-011: ATLAS-Enabled T cell Therapy for Solid Tumors
GEN - 011 ATLAS-Enabled T cell Therapy for Solid Tumors Autologous T cell therapy Advancing rapidly to the clinic T cells expanded from peripheral blood : Proof of concept for key IND - e n a b l i n g activities has been achieved: • Both CD4 + and CD8 + T cells with validated antigen • CMC activiti
Slide 24: Driving the Next-Generation of Immunotherapies
Driving the Next-Generation of Immunotherapies U n i q u e Differentiated Next-generation Antigen validation Clinical responses: Neoantigen cell therapy platform, ATLAS, enables Phase 1/2a GEN-009 product candidate GEN- personalized immune (neoantigen vaccine) 011, with IND filing 1H response profil
Slide 25: Acorn Park Drive, Cambridge, MA contact details
NASDAQ: GNCA 100 Acorn Park Drive Cambridge, MA 02140 USA +1 617.876.8191 | CONFIDENTIAL www.genocea.com25
Genocea Biosciences — Investor Presentation (November 2019) on 6ix